More MS news articles for June 2002

High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12077287&dopt=Abstract

J Immunol 2002 Jul 1;169(1):548-56
Weissert R, Kuhle J, De Graaf KL, Wienhold W, Herrmann MM, Muller C, Forsthuber TG, Wiesmuller KH, Melms A.
Departments of. Neurology and Transplantationimmunology and Immunehematology, University of Tubingen, Tubingen, Germany. Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106. EMC Microcollections, Tubingen, Germany.

Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the CNS with associated axonal loss.

There is strong evidence for an autoimmune pathogenesis driven by myelin-specific T cells.

Myelin oligodendrocyte glycoprotein (MOG) induces a type of experimental autoimmune encephalomyelitis in animals which is very MS-like since there are demyelinating CNS lesions and axonal loss.

This underscores the potential role of MOG in MS pathogenesis.

We performed a T cell reactivity pattern analysis of MS patients at the onset of relapse or progression of neurological deficits and controls that were stratified for the genetic risk factor HLA-DRB1*1501.

For the first time, we show that there is an HLA-DR-restricted promiscuous dominant epitope for CD4(+) T cells within the transmembrane/intracellular part of MOG comprising aa 146-154 (FLCLQYRLR).

Surprisingly, controls had broader T cell reactivity patterns toward MOG peptides compared with MS patients, and the transmembrane and intracellular parts of MOG were much more immunogenic compared with the extracellular part.

Measurements of in vitro binding affinities revealed that HLA-DRB1*1501 molecules bound MOG 146-154 with intermediate and HLA-DRB1*0401 molecules with weak affinities.

The binding of MOG 146-154 was comparable or better than myelin basic protein 85-99, which is the dominant myelin basic protein epitope in context with HLA-DRB1*1501 molecules in MS patients.

This is the first study in which the data underscore the need to investigate the pathogenic or regulatory role of the transmembrane and intracellular part of MOG for MS in more detail.